The Impact of Estrogen Administration Duration in Hormonally Prepared Frozen Embryo Transfer Cycles

NCT05825885 | Completed

• 1 other identifier: 498496942
• Study Type: observational
• Target: 420
• Locations: 1 country
• Sites: 1

Brief Summary

This prospective controlled study aimed to investigate the effect of the duration of estrogen (E2) administration prior to progesterone (P) initiation on live birth rates (LBR) in frozen embryo transfer (FET) cycles. The study was conducted at a single tertiary-care in vitro fertilization (IVF) center and included 486 patients undergoing high-quality frozen blastocyst transfer in a hormone replacement therapy (HRT) cycle. Patients scheduled for E2 therapy were administered either 5-7, 8-10, or 11-13 days of treatment, depending on their presentation day. After the E2-only phase, if the endometrial thickness was above 7mm, P was initiated (daily 300mg of vaginal micronized P tablets), and FET was performed on the 6th day of P treatment. The primary outcome measure was LBR.

Conditions

Duration of Estrogen Administration

Keywords

Endometrial compaction; Endometrial receptivity; Endometrial thickness; Frozen embryo transfer; HRT; Pregnancy

Outcome Measures

Primary Outcomes (1)

• live birth rate

  the birth ratio of a baby who showed any sign of life

  2 years

Secondary Outcomes (3)

• implantation rate

  2 years

• clinical pregnancy rate

  2 years

• miscarriage rate

  2 years

Study Arms (3)

5-7 days E2 therapy

Patient group treated with e2 for 5-7 days

8-10 days E2 therapy

Patient group treated with e2 for 5-7 days

11-13 days E2 therapy

Patient group treated with e2 for 5-7 days

Interventions

E2 DRUG

micronized E2 at a daily dose of 4-6mg,

Eligibility Criteria

• Age: 18 Years - 40 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

All patients who have artificial endometrial preparation with high-quality blastocysts between January 2020 and December 2021 were included.

You may qualify if:

• Exogenous hormone preparation of the endometrial lining
• High embryo quality ((≥2BB) according to Alpha criteria
• Embryo transfer at the blastocyst stage

You may not qualify if:

• \- Patients whose treatments were canceled for any reason before the embryo transfer procedure
• Patients who underwent embryo transfer in the cleavage stage
• Presence of low-quality (\<2BB) blastocysts
• \>15% loss of viability of the embryo during embryo thawing,

Sponsors & Collaborators

• Akdeniz University: lead

Study Sites (1)

Akdeniz University

Antalya, Antalya, 07700, Turkey (Türkiye)

Location

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: April 11, 2023
• First Posted: April 24, 2023
• Study Start: January 1, 2020
• Primary Completion: December 31, 2021
• Study Completion: May 1, 2023
• Last Updated: February 27, 2025

Record last verified: 2025-02

Locations

TU (1)